Table 1. Selected characteristics.
| PLCO1 | ATBC2 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Controls | P3 | Cases | Controls | P3 | ||||||||
| Characteristic | N | (%) | N | (%) | Characteristic | N | (%) | N | (%) | ||||
| Total | 299 | (100.0) | 676 | (100.0) | NA | Total | 391 | (100.0) | 778 | (100.0) | NA | ||
| Gender | |||||||||||||
| Male | 242 | (80.9) | 560 | (82.8) | Male | 391 | (100.0) | 778 | (100.0) | ||||
| Female | 57 | (19.1) | 116 | (17.2) | 0.47 | - | |||||||
| Age at randomization (years) | |||||||||||||
| - | 50–55 | 113 | (28.9) | 239 | (30.7) | ||||||||
| 55–59 | 70 | (23.4) | 147 | (21.7) | 55–59 | 130 | (33.2) | 250 | (32.1) | ||||
| 60–64 | 91 | (30.4) | 216 | (32.0) | 60–64 | 99 | (25.3) | 197 | (25.3) | ||||
| 65–69 | 87 | (29.1) | 191 | (28.3) | 65–70 | 49 | (12.5) | 92 | (11.8) | 0.92 | |||
| 70–74 | 51 | (17.1) | 122 | (18.0) | 0.90 | - | |||||||
| Age at blood draw (years) | |||||||||||||
| - | 54 | 5 | (1.3) | 23 | (3.0) | ||||||||
| 55–59 | 22 | 7.4 | 84 | 12.4 | 55–59 | 100 | (25.6) | 194 | (24.9) | ||||
| 60–64 | 84 | 28.1 | 169 | 25.0 | 60–64 | 137 | (35.0) | 275 | (35.4) | ||||
| 65–69 | 95 | 31.8 | 213 | 31.5 | 65–69 | 96 | (24.6) | 184 | (23.7) | ||||
| 70–79 | 98 | 32.8 | 210 | 31.1 | 0.12 | 70–76 | 53 | (13.6) | 102 | (13.1) | 0.52 | ||
| Center | |||||||||||||
| Colorado | 24 | (8.0) | 55 | (8.1) | Kouvola | 17 | (4.3) | 35 | (4.5) | ||||
| Georgetown | 18 | (6.0) | 40 | (5.9) | Kotka | 22 | (5.6) | 35 | (4.5) | ||||
| Henry Ford | 28 | (9.4) | 57 | (8.4) | Helsinki | 109 | (27.9) | 220 | (28.3) | ||||
| Minnesota | 98 | (32.8) | 184 | (27.2) | Jyvaskyla | 29 | (7.4) | 65 | (8.4) | ||||
| Washington | 34 | (11.4) | 60 | (8.9) | Hameenlinna | 24 | (6.1) | 43 | (5.5) | ||||
| Pittsburgh | 28 | (9.4) | 102 | (15.1) | Lahti | 25 | (6.4) | 36 | (4.6) | ||||
| Utah | 25 | (8.4) | 70 | (10.4) | Meltola | 6 | (1.5) | 13 | (1.7) | ||||
| Marshfield | 36 | (12.0) | 96 | (14.2) | Pori | 30 | (7.7) | 44 | (5.7) | ||||
| Alabama | 8 | (2.7) | 12 | (1.8) | 0.19 | Tampere | 35 | (9.0) | 77 | (9.9) | |||
| Salo | 9 | (2.3) | 17 | (2.2) | |||||||||
| Seinajoki | 31 | (7.9) | 68 | (8.7) | |||||||||
| Tutku | 40 | (10.2) | 108 | (13.9) | |||||||||
| Rauma | 14 | (3.6) | 17 | (2.2) | 0.66 | ||||||||
| Years between age at blood draw and case dx and matching for controls | |||||||||||||
| ≤1 | 69 | (23.1) | 149 | (22.0) | ≤1 | 43 | (11.0) | 95 | (12.2) | ||||
| 2–3 | 83 | (27.8) | 190 | (28.1) | 2–3 | 53 | (13.6) | 92 | (11.8) | ||||
| 4–6 | 86 | (28.8) | 182 | (26.9) | 4–6 | 68 | (17.4) | 133 | (17.1) | ||||
| 7–13 | 61 | (20.4) | 155 | (22.9) | 0.81 | 7–13 | 191 | (48.9) | 383 | (49.2) | |||
| 14–16 | 36 | (9.2) | 75 | (9.6) | 0.91 | ||||||||
| Pack-Years of Smoking | |||||||||||||
| 0 | 75 | (25.5) | 304 | (45.4) | - | ||||||||
| 1–20 | 51 | (17.3) | 120 | (17.9) | 1–20 | 56 | (14.3) | 187 | (24.0) | ||||
| 21–40 | 57 | (19.4) | 116 | (17.3) | 21–40 | 166 | (42.5) | 339 | (43.6) | ||||
| 41–60 | 52 | (17.7) | 77 | (11.5) | 41–60 | 125 | (32.0) | 197 | (25.3) | ||||
| >60 | 59 | (20.1) | 53 | (7.9) | <0.0001 | >60 | 44 | (11.3) | 55 | (7.1) | <0.001 | ||
N, number; NA, not applicable; dx, diagnosis; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Cohort. 1PLCO included 7 cases also selected as controls prior to diagnosis, and 10 controls randomly selected as controls twice. 2ATBC did not include cases also selected as controls and 110 controls were randomly matched to more than 1 case. 3χ2 P value.